Harmony Biosciences — Q3 2026 Earnings Summary

Harmony Biosciences reported third-quarter 2026 net revenue of $268.9 million for its product WAKIX, driven by a 400-patient increase to reach 9,350 total patients. The company reiterated its full-year WAKIX net revenue guidance of $1.0 billion to $1.04 billion and announced that its investigational orexin agonist BP-205 demonstrated favorable safety and pharmacokinetic profiles in a multiple-ascending dose study. Leadership transition is scheduled for January 1, 2027, when Peter Anastasiou will succeed Jeffrey Dayno as President and Chief Executive Officer. Additionally, the company confirmed that the Pitolisant GR NDA is under FDA review with a PDUFA date of April 1, 2027, and highlighted a multi-layered intellectual property strategy supporting exclusivity through March 2030.